{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:04:43Z","timestamp":1771268683154,"version":"3.50.1"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2013,11,11]],"date-time":"2013-11-11T00:00:00Z","timestamp":1384128000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0062264","type":"journal-article","created":{"date-parts":[[2013,11,11]],"date-time":"2013-11-11T23:37:02Z","timestamp":1384213022000},"page":"e62264","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer"],"prefix":"10.1371","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct01032291","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Salvatore","family":"Siena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Jungnelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Bencardino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elena","family":"Elez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Prenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia","family":"Sanchis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Sartore-Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Tejpar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,11,11]]},"reference":[{"key":"ref1","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/globocan.iarc.fr\" xlink:type=\"simple\">http:\/\/globocan.iarc.fr<\/ext-link>. Accessed 07 November 2011."},{"key":"ref2","unstructured":"Weinberg RA (2007) Multi-steptumorigenesis. In: Weinberg RA. The biology of cancer. New York: Garland Science. pp. 399\u2013462."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/jnci\/djp280","article-title":"Biomarkers predicting clinical outcome of epidermal growth factor receptor \u2013 targeted therapy in metastatic colorectal cancer","volume":"101","author":"S Siena","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CCC.2006.n.01","article-title":"Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer","volume":"6","author":"TB Gibson","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"D Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"LB Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/0008-5472.CAN-06-4158","article-title":"Oncogenic activation of the RAS\/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies","volume":"67","author":"S Benvenuti","year":"2007","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","article-title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer","volume":"66","author":"A Li\u00e8vre","year":"2006","journal-title":"Cancer Res"},{"key":"ref9","unstructured":"NCCN clinical practice guidelines in oncology: Colon Cancer v3.2012. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf\" xlink:type=\"simple\">http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf<\/ext-link>. Accessed 21 November 2012."},{"key":"ref10","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","author":"A Grothey","year":"2012","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1200\/JCO.2011.36.1980","article-title":"Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer","volume":"29","author":"JC Bendell","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref12","article-title":"Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC)","volume":"30 suppl 15","author":"JC Bendell","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"DJ Jonker","year":"2007","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/PPO.0b013e318172d71a","article-title":"Antibody-based therapy for solid tumors","volume":"14","author":"L Yan","year":"2008","journal-title":"Cancer J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/erc.0.0100001","article-title":"Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment","volume":"10","author":"N Normanno","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"S Li","year":"2005","journal-title":"Cancer Cell"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1128\/CDLI.1.6.640-644.1994","article-title":"Genetic diversity in human Fc receptor II for immunoglobulin G: Fc gamma receptor IIA ligand-binding polymorphism","volume":"1","author":"AF Reilly","year":"1994","journal-title":"Clin Diagn Lab Immunol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/infdis\/170.4.854","article-title":"Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections","volume":"170","author":"LA Sanders","year":"1994","journal-title":"J Infect Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood-2007-03-079913","article-title":"Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura","volume":"111","author":"WB Breunis","year":"2008","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.autrev.2007.01.017","article-title":"Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus","volume":"6","author":"M Kavai","year":"2007","journal-title":"Autoimmun Rev"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2265.2010.03780.x","article-title":"Association of FcGRIIa with Graves&apos; disease: a potential role for dysregulated autoantibody clearance in disease onset\/progression","volume":"73","author":"K Yesmin","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"G Cartron","year":"2002","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1600-0609.2008.01174.x","article-title":"FCGR3A-158V\/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin&apos;s lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation","volume":"82","author":"M Nishio","year":"2009","journal-title":"Eur J Haematol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"A List","year":"2006","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"M Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"DM Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6600607","article-title":"Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects","volume":"87","author":"K Dredge","year":"2002","journal-title":"Br J Cancer"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-010-0919-9","article-title":"Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers","volume":"60","author":"L Wu","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/0091270009335001","article-title":"Phase I study of oral lenalidomide in patients with refractory metastatic cancer","volume":"49","author":"WL Dahut","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/01.JTO.0000268679.33238.67","article-title":"Phase I study of lenalidomide in solid tumors","volume":"2","author":"AA Miller","year":"2007","journal-title":"J Thorac Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.ejca.2006.05.018","article-title":"Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies","volume":"42","author":"RA Sharma","year":"2006","journal-title":"Eur J Cancer"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00262-009-0697-4","article-title":"Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells","volume":"58","author":"A L\u00f3pez-Albaitero","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1200\/JCO.2006.08.8021","article-title":"FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab","volume":"25","author":"W Zhang","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","article-title":"Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study","volume":"6","author":"M Moroni","year":"2005","journal-title":"Lancet Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2007.11.5956","article-title":"Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab","volume":"25","author":"A Sartore-Bianchi","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-08-0449","article-title":"Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study","volume":"14","author":"N Personeni","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/jclinpath-2011-200353","article-title":"Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study","volume":"65","author":"A Sartore-Bianchi","year":"2012","journal-title":"J Clin Pathol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0062264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T10:27:14Z","timestamp":1716114434000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0062264"}},"subtitle":[],"editor":[{"given":"Salomon M.","family":"Stemmer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,11,11]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2013,11,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0062264","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,11]]}}}